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Adrenal steroid (AS) receptors differ from other steroid receptors in the inability of the activated form of the cytosolic receptor to exchange 
ligand in an in vitro binding assay. We extended this finding by demonstrating that AS receptors extracted from isolated brain nuclei also failed 
to exchange ligand. Taking advantage of this unique feature of AS receptors, we measured type I and type II AS binding level in rats with 
varying amounts of endogenous glucocorticoids or exogenous dexamethasone (DEX). We estimated the degree of receptor occupation/ 
activation in various brain areas and the pituitary during basal glucocorticoid conditions and after acute stress. There was a variable proportion 
of type I receptors in the hippocampus which were unactivated during basal conditions (0-35%). The proportion of unactivated type I receptors 
increased (55-65%) after DEX treatment. The hippocampus was especially sensitive to the ability of low basal corticosterone (CORT) levels 
to activate both type I and type II receptors, whereas the pituitary was very insensitive, evidenced by a failure of acute stress levels of 
endogenous glucocorticoids to occupy/activate type II receptors in the pituitary. Comparison of estimates of the degree of in vivo hippocampal 
type I and type II receptor activation for the various treatment groups with estimates of in vitro type I and type II receptor occupation by 
steroid suggested that DEX was more efficient than CORT in producing or maintaining the activated form of the type II receptor in vivo, 
whereas CORT was more efficient than DEX in activating the type I receptor. These studies suggest that AS receptors in the brain, and 
especially the hippocampus, are more sensitive to circulating levels of glucocorticoids than the pituitary. There also may be a greater capacity 
for physiological variations in type I receptor occupation in vivo than had previously been suggested. Finally, discrepancies between CORT 
and DEX affinity in vitro for type I and type II sites and their in vivo potency may be accounted for by differences in the ability of these 
compounds to activate type I and type II AS receptors. 
INTRODUCTION 
Recep tors  for adrenal  s teroids (AS)  are found in cells 
th roughout  the body,  including the brain.  Two separate ,  
high-affinity receptors  for AS have been character ized by 
recep tor  binding studies 27'41, and recent ly c D N A  clones 
corresponding to the genes for these two receptors  have 
been isolated and sequenced 1'14. One receptor ,  type I, 
has a high affinity (K d = 1 nM or  less) for both  the 
minera locor t icoid ,  a ldos terone ,  and the glucocorticoids,  
cort isol  and cor t icos terone ( C O R T ) ,  and a 3- to 5-fold 
lower affinity for the synthetic glucocort icoid,  dexameth-  
asone ( D E X )  2'27'36. The second receptor ,  type II ,  has a 
high affinity for D E X  (K d less than 1 nM),  a 3- to 5-fold 
lower  affinity for CORT,  and 10- to 20-fold lower affinity 
for  a ldos te rone  27'41. 
Within the brain there  is regional  variat ion in the 
density of both  the type I and type II  AS receptors ,  which 
is para l le led  by the concentra t ion of their  respective 
m R N A  7. The  densi ty of type II  receptors  is more  uniform 
than the type I recep tor  and in most  bra in  regions is 
about  10 t imes higher in concentra t ion than the type I 
receptor .  The h ippocampal -sep ta l  system stands out  as 
having except ional ly  high concentra t ions  of the type I 
recep tor  and in the h ippocampus  approaches  almost  50% 
of  the concentra t ion of the type II recep tor  4. 
The presence of AS receptors  in the bra in  confers on 
the brain the abili ty to detect  and respond  to varying 
levels of glucocorticoids.  The  response  of  the brain to 
glucocorticoids may be modif ied  by changes in AS 
receptor  number .  A decrease  of A S  receptors  in rat  brain 
has been repor ted  after glucocort icoid t rea tment ,  chronic 
stress, or  in aged rats 31'33'39. Diurnal  variat ions in AS 
receptor  number  have also been found 7'28. 
Prevail ing models  of  s teroid recep tor  action propose  
that  the receptor ,  when bound  by steroid,  undergoes  a 
conformat ional  change,  referred to as activation or  
t ransformat ion 23'4z. The act ivated form of the receptor  
has a high affinity for D N A  and is found exclusively in 
the nucleus, whereas  the unact ivated form of the receptor  
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has a much  lower  affinity for  D N A  and e i ther  resides in 
the  ex t r anuc l ea r  cytosol ic  c o m p a r t m e n t  and t rans locates  
to the  nucleus  upon  ac t iva t ion  or  resides in the  nucleus  
but  ' l eaks '  in to  the  cytosol  dur ing t issue h o m o g e n i -  
za t ion  12"42. T h e  A S  type  II  r ecep to r ,  and pe rhaps  also the  
type I r ecep to r ,  are  un ique  f rom o the r  s teroid  recep tors ,  
in that  only  the  unac t iva ted  fo rm of  the  cytosol ic  r ecep to r  
can reb ind  s tero id  and par t ic ipa te  in an in vi t ro  exchange  
assay 9. Thus ,  the  ob ta ined  Bma× for  type 1 or  type II 
r e c e p t o r  b inding indicates  only  the n u m b e r  o f  unact iva-  
ted  recep to r s  p resen t  in the  cytosol  pool .  Consequen t ly ,  
s tudies o f  cytosol ic  A S  r ecep to r  b inding have  rou t ine ly  
been  c o n d u c t e d  on rats which were  a d r e n a l e c t o m i z e d  in 
o r d e r  to e l imina te  the p re sence  of  e n d o g e n o u s  C O R T  
and subsequen t  r ecep to r  ac t ivat ion.  
In this s tudy we use this un ique  fea ture  of  A S  recep to r  
b inding to eva lua te  the level  o f  r ecep to r  occupa t ion  and 
ac t iva t ion  in var ious  bra in  regions  and pi tui tary  dur ing 
man ipu la t ions  o f  e n d o g e n o u s  and exogenous  s tero id  
levels.  We have  e x a m i n e d  bo th  type I and type II  A S  
r e c e p t o r  b ind ing  for  intact  rats  at the  nad i r  of  their  
C O R T  circadian cycle. In addi t ion ,  the  level  of  endoge -  
nous C O R T  (the p r imary  g lucocor t ico id  in the  rat)  at the  
t ime  of  sacrif ice was e l eva ted  in s o m e  rats by expos ing  
t h e m  to acute  stress,  r educed  in o thers  by adminis te r ing  
to t h e m  a dr ink ing  wa te r  solut ion conta in ing  D E X  29'35, 
and  e l im ina t ed  in o the r s  by 16 h a d r e n a l e c t o m y  ( A D X ) .  
We have  also e x a m i n e d  the  r ecep to r  b inding in each  
cond i t ion  across a range  of  rad io l igand  concen t ra t ions  
r a the r  than  at a single sa tura t ing  concen t r a t ion  so that  we 
can e s t ima te  the  a m o u n t  of  c o m p e t i n g  s teroid  p resen t  in 
the  cytosol  ( d e t e r m i n e d  by the  deg ree  of  shift in Ko) as 
well  as the  m a x i m u m  n u m b e r  of  b inding sites (Bmax). We 
also r epo r t  he re  the  resul ts  o f  ou r  a t t empts  to measu re  in 
an in v i t ro  exchange  assay specific b inding of  ex t rac ted  
A S  r e c e p t o r  p ro te in  f r o m  isola ted  nuclei .  
MATERIALS AND METHODS 
Animals 
For each experiment animals were male Sprague-Dawley rats 
(175-250 g). Animals were housed in hanging wire mesh cages (3 
per cage) in an animal room separate from the laboratory. The 
animal room was maintained on a 14:10 day-night cycle with lights 
on at 05.00 h. The animals were given rat chow and tap water ad 
libitum, except after ADX, in which case 0.9% saline was 
substituted for tap water. 
Steroids 
[1,2,6,7-3H(N)]Corticosterone (112 Ci/mmol) and [6,7-3H(N)]dexa - 
methasone (39-50 Ci/mmol) were obtained from New England 
Nuclear (Boston, MA). [1,2-3H(N)]Aldosterone (75 Ci/mmol) was 
obtained from Amersham (Arlington Heights, IL). Unlabeled CORT 
was obtained from Steraloids (Wilton, NH) and DEX from Sigma (St. 
Louis, MO). The selective type II receptor agonist, RU26988, was a 
gift from Roussel-Uclaf (Romainville, France). 
A drenalectomy 
Bilateral adrenalectomy was performed on animals fully anesthetized 
with the inhalant, Metofane (Pitman-Moore, Washington Crossing, 
N J). Aseptic surgical procedure was used. 
Experiment 1 
In the first experiment we compared the levels of type I and type II 
AS receptor binding in 16 h ADX and intact unstressed or stressed 
rats. The 3 treatment groups were designated as ADX, intact/no-stress 
and intact/stress. There were 3 rats per group and the experiment was 
repeated on 3 separate occasions. The intact/no-stress rats were killed 
at either 07.00 or 09.00 h in the room in which they were housed. The 
ADX and intact/stress rats were transferred at 09.00 h to portable 
cages, placed on a cart and transported to a room on a different floor, 
where they were killed 30 min later. The intact/stress rats had no 
experimentally induced stress in this experiment other than that 
resulting from handling and transport and they did not differ from the 
ADX rats in that regard other than their exposure to an elevation of 
endogenous CORT. Rats were decapitated and trunk blood was 
collected for serum CORT determinations. Brains were removed, 
dissected on ice and tissue rapidly frozen and stored at -80 °C for 
subsequent binding studies. 
Experiment 2 
In the second experiment we repeated the basic procedure of the first 
experiment, but included groups of 16 h ADX rats and intact/no-stress 
rats which were given DEX in their drinking water (1.5/~g/ml) for 16 h 
prior to sacrifice. The five treatment groups were designated as ADX, 
ADX/DEX, intact/no-stress, intact/stress and intact/DEX. The pri- 
mary purpose of the DEX treatment was to see if the suppression of 
endogenous CORT levels by the DEX treatment would result in a 
higher detectable level of type I binding in the intact rat. The stress 
procedure in this experiment was modified. As in the first experiment, 
the intact/stress rats were transported to a room on a different floor 
from their home cage. They were then given, in addition, 1 h of 
restraint stress (plexiglass restrainers) from 08.00 to 09.00 h and were 
decapitated immediately after restraint. The intact/no-stress and 
intact/DEX rats were killed at 07.30 h in their home room. The ADX 
and ADX/DEX rats were also transported to another room and killed 
between 08.00 and 09.00 h. As in the first experiment, there were 3 rats 
per treatment group, and the experiment was repeated on 3 separate 
occasions. Type I binding was measured with both [3H]DEX and 
[3Hlaldosterone in order to compare the adequacy of both ligands for 
measuring type I binding in vitro. On one occasion type I and type II 
single point binding of individual hypothalamus, cortex, cerebellum 
and pooled pituitary was examined for the 3 treatment groups, ADX, 
intact/no-stress and intact/stress. The data were combined with the 
single point values for the same brain areas and treatments obtained in 
Expt. 1. 
Experiment 3 
The third experiment examined the effect of increased duration and 
dose of DEX treatment on receptor binding. Groups of intact rats, 3 
or 4 per group, were given DEX (1/zg/ml) in their drinking water for 
either 1, 2 or 3 days or a higher dose of DEX (5/tg/ml) in the drinking 
water for 3 days. The drinking water was not removed prior to time of 
sacrifice. A group of 16 h ADX rats was included for comparison. 
Experiment 4 
The procedure and treatment groups in the 4th experiment were the 
same as the second experiment except that the dose of DEX in the 
drinking water was increased to 15/~g/ml. There were 3 rats per group 
and the experiment was performed only once. 
Binding assay 
Tissue was homogenized (15 strokes at 1000 rpm) with a motor- 
driven Teflon pestle and glass tube on ice and then centrifuged 
(Beckman Ultracentrifuge) at 105,000 g for 60 min at 4 °C. The 
supernatant/cytosol was then added to incubation solutions containing 
radiolabeled steroids with or without unlabeled competitors. Cytosol 
was incubated at 4 °C with steroids overnight (18-22 h). Columns 
containing 1.25 ml of LH-20 Sephadex (Pharmacia) were used to 
separate bound from free steroid. The eluate containing bound steroid 
was collected directly into scintillation vials. Scintillation finor (Liqui- 
scint) was added to the vials and tritium radioactivity counted on a 
scintillation counter (Packard Series 1599 Tri-Carb, 45% efficiency). 
The homogenization and incubation buffer (TEGMD) was com- 
prised of 10 mM Tris, 1 mM EDTA, 20 mM molybdic acid, 5 mM 
dithiothreitol and 10% glycerin in double distilled water (pH = 7.4). 
Pooled hippocampi were homogenized in buffer (2.2 ml/hippocampus) 
yielding a final protein concentration of 1.0-1.3 mg protein/ml cytosol. 
Tissues from other brain regions were homogenized in a volume of 1.5 
ml buffer, yielding a final protein concentration of 0.5-1.5 mg 
protein/ml cytosol, q~ae II binding was derived from the binding of 
[3H]DEX with or without the presence of the selective type II 
competitor, RU26988 (0.5/~M) 22. See tables and figure legends for 
specific radioligand concentrations used in each experiment. Type I 
binding was determined from the binding of [3H]DEX or [3H]- 
aldosterone in the presence of RU26988 (0.5/~M). Binding in the 
presence of an excess of CORT (2,5/~M) was used for determining 
non-specific binding. Non-specific binding was reliably less than 5% of 
total binding. For saturation binding assays, five different concentra- 
tions of radiolabeled ligand were used, and for single point binding 
assays a single saturating concentration of radiolabeled ligand was 
used. Specific binding was expressed as fmol/mg of cytosol protein. 
Protein content was determined by the method of Bradford 3, with use 
of bovine serum albumin (BSA) as a standard. 
We have found that in vitro, [3H]DEX is an effective radioligand for 
measuring type I AS receptors. Saturation binding of [aH]DEX (in the 
presence of 0.5 #M RU26988) to type I receptors in hippocampal 
cytosol from ADX rats resulted in a surprisingly low mean _+ S.E.M. 
Kd of 1.22 + 0.12 nM (n = 10) which was only 2-fold higher than that 
obtained with [3H]aldosterone binding in the presence of 0.5 gM 
RU26988 (0.69 + 0.07 nM, n = 7). Furthermore, competition studies 
which compared the ICs0 for a number of steroids on [3H]DEX or 
[3H]aldosterone binding of hippocampal cytosol from ADX rats (in the 
presence of 0.5/zM RU26988), resulted in an identical rank order of 
potency and a Pearson r, correlation coefficient, of 0.93. The rank 
order potency of competing steroids was as follows: RU26752 > 
aldosterone, CORT, deoxycorticosterone > cortisol > progesterone, 
cortexolone, DEX > 17-a-progesterone > 11-dehydroxy-cortico- 
sterone. 
Nuclear isolation and exchange assay 
An attempt was made to use an exchange assay to measure AS 
receptor extracted from isolated nuclei. This was based on the 
procedure routinely used for measuring estrogen receptor 3°. If suc- 
cessful, the procedure would allow for determination of receptor that 
was occupied and activated and would eliminate the requirement of 
ADX for making estimates of receptor number. 
Rats were ADX several days in advance of the experiment. On the 
day of the experiment rats were treated with 1 of 4 injection conditions; 
a low dose of radiolabeled [3H]CORT (150/~Ci in 0.9% saline, i.m.), 
a similar dose of unlabeled CORT (0.5/tg in 0.9% saline, i.m.), a high 
dose of CORT (50 mg/kg in sesame oil, s.c.), or a control injection of 
sesame oil (1 mFkg, s.c.). The radiolabelled steroid was given i.m. 
instead of the more traditional s.c. route in order to increase the rate 
of uptake. The ADX group given sesame oil provided a negative 
control group from which we expected no nuclear localization of AS 
receptors, whereas with low and high CORT treatment we expected 
moderate to high levels of AS receptors in the nuclear extract. The 
injection of [3H]CORT to one group of rats provided for an estimate 
of the number of AS receptors in the nuclear extract from rats with low 
CORT treatment. One hour after injection rats were killed and brains 
were rapidly removed on ice and nuclei were isolated from either whole 
brain or in some cases from specific brain regions according to the 
procedure described previously ~. Nuclear proteins were extracted with 
the addition of 0.6 M KC1. The isolated nuclei were suspended twice 
in 1.5 ml TEGMD buffer containing 0.6 M KCI and centrifuged for 10 
rain at 850 g and the resulting supernatant collected and pooled for 
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each sample. Aliquots of the sample from rats given an injection of 
radiolabeled CORT were either directly mixed with scintillation 
cocktail and radioactivity counted in a scintillation counter or were first 
incubated with or without an excess of unlabeled CORT (2.5/~M) and 
then radioactivity of bound steroid (separated from free using LH-20 
Sephadex columns as described above) was counted. Nuclear extracts 
from the other treatment groups were added to exchange assay 
incubation vials. Binding of [3H]CORT (1 nM) was examined in the 
exchange assay. Unlabeled CORT (2.5 ~M) was used to determine 
non-specific binding. DNA content of nuclear pellets was determined 
by the method of Burton 5. 
CORT measurement 
Serum CORT was measured by radioimmunoassay using rabbit 
antiserum raised against CORT-21-hemisuccinate BSA (B21-42, En- 
docrine Sciences, Tarzana, CA). Assay sensitivity was 10 pg of CORT, 
and coefficients of variation within and between assays were 4% (n = 
3) and 8% (n = 7), respectively. 
Data analysis and statistics 
For saturation binding studies the binding parameters, dissociation 
constant (Kd) and binding maximum (Bm~), were derived from 
Scatchard analysis 17. Analysis of variance was used for testing overall 
differences between treatment groups for the various dependent 
measures. The Newman-Keuls test (or Tukey test, in the case of 
unequal group size) was used for tests of significant differences between 
specific means. Changes in binding levels are reported relative to the 
binding level of the 16 h ADX rats in that particular experiment. Data 
are expressed as mean + S.E.M. 
RESULTS 
Experiment 1. Occupation~activation o f  type I and type H 
receptors in stress and no stress conditions in hippocam- 
pus, other brain regions, and pituitary 
In  o r d e r  to  inves t iga te  the  h o r m o n a l  cond i t ions  unde r  
which type  I and type  II  r ecep to r s  a re  occup ied  in v ivo  
by e n d o g e n o u s  g lucocor t ico ids ,  we  used  sa tu ra t ion  anal-  
ysis to c o m p a r e  r e c e p t o r  b inding  in the  h i p p o c a m p u s  o f  
3 t r e a t m e n t  groups:  A D X ,  in tac t /no-s t ress  and  in tact /  
stress (Table  I).  Us ing  va lues  f r o m  the  16 h A D X  rats as 
a r e f e r ence ,  the  Bma x for  type  I I  r e c e p t o r  b inding  was 
about  20% lower  in the  h i p p o c a m p u s  o f  the  intact /  
no-s t ress  rats,  wi th  no change  in K a. T h e  intact /s t ress  rats  
had  abou t  a 40% lower  Bma x and  a 5 t imes  g rea t e r  K d. 
T h e  p r e sence  of  e n d o g e n o u s  g lucocor t i co id  had a 
g rea te r  effect  on  the  type  I r e c e p t o r  measures .  In  n o n e  
o f  the  intact /s t ress  rat  samples  was t he r e  e n o u g h  of  a type  
I signal to p e r f o r m  a Sca tchard  analysis.  In te res t ing ly ,  for  
the  in tac t /no-s t ress  rats t he r e  was a va r i ab le  type  I signal. 
O n  two occas ions  t he r e  was no  signal ,  w h e r e a s  on  the  
o the r  the re  was a smal l  signal wi th  a Bm~ x abou t  2 0 %  of  
that  for  the  16 h A D X  group.  
T h e  stress used  in this first e x p e r i m e n t ,  i . e . ,  t r anspor t -  
ing rats f r o m  the i r  h o m e  cage  to a s epa ra t e  r o o m  for  
sacrif ice 30 min  la ter ,  p r o d u c e d  a rise in s e rum C O R T  
levels  of  40.5 + 6 . 5 / ~ g %  c o m p a r e d  to an ave rage  level  
of  3.6 + 1 .1 /~g% for  the  in tac t /no-s t ress  g roup .  O n  one  
occas ion  we split the  poo l  o f  h i p p o c a m p a l  cytosol  
o b t a i n e d  f r o m  intact /s t ress  rats  and f i l te red  half  of  the  
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TABLE I 
Glucocorticoid receptor binding (mean +_ S.E.M.) of hippocampal 
cytosol from 16 h A DX or intact rats with or without stress 
Hippocampi were pooled from 3 rats for each treatment group and 
the mean and S.E.M. represent the results from 3 separate 
experiments. Type I binding was measured with [3H]DEX (1-30 nM) 
in the presence of RU26988 (0.5pM), and non-specific type I binding 
was determined from [3H]DEX binding in the presence of an excess 
of CORT (2.5/~M). Type II binding was measured with [3H]DEX 
(1-30 nM) with or without the presence of RU26988 (0.5/~M). n.d., 
not detectable. 
Treatment Type I binding Type H binding 
Kd B "~ Kd Bmax 
(nM) (fmol/mg) (nM) (fmol/mg) 
ADX 1.42+0.22 103.7+23.6 0.50+0.10 259.8+36.8 
Intact/ 
no-stress - 6.7 + 6.7** 0.40 + 0.12 177.7 + 9.5* 
Intact/stress n.d. 2,69 + 0.84* 157.1 + 6.2* 
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Fig. 2. Brain region and pituitary comparison of type I binding of 
ADX rats and intact stressed and unstressed rats. Type I binding for 
the hypothalamus, cortex, cerebellum and pituitary was measured 
with a single saturating concentration of [3H]aldosterone (6 nM) in 
the presence of RU26988 (0.5/zM), n = 4-6. The hippocampal 
binding shown is the combined Bma X values from Expts. 1, 2 and 4 
(see Tables I-III) for the 3 treatment groups, n = 7. *P < 0.01, 
significantly different from the ADX group for the same tissue area, 
Tukey test. 
cy tosol  t h rough  an LH-20  Sephadex  co lumn  in an effor t  
to strip the  u n b o u n d  e n d o g e n o u s  cor t icos te ro id  f rom the  
cytosol  pr ior  to use in the  exchange  assay, As  shown in 
Fig. 1, this p r o c e d u r e  r educed  the K d for the  type II 
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that  the  e l eva t ion  in K d was a resul t  of  the  p re sence  of  
c o m p e t i n g  s tero id  r a the r  than  an intr insic change  in 
r ecep to r  affinity. T h e r e  was no  m e a s u r a b l e  type  I b inding 
for  e i the r  f rac t ion of  cytosol .  
O t h e r  bra in  areas  and the  p i tu i ta ry  were  inves t iga ted  
using single po in t  b inding assays for  type  I and type  II  
receptors .  In mos t  cases the re  was a small ,  but  de tec t -  
able ,  type I signal for  the  in tac t /no-s t ress  rats,  and 
s o m e t i m e s  for the  intact /s t ress  rats.  T h e r e  was a signifi- 
cant  dec rease  in cor t ica l  type  I b inding for  the  intact /  
no-stress  g roup  c o m p a r e d  to A D X  levels  and a dec rease  
~]ADX 16 nr 
[~ Intact/No Stress 
200 400 [] Intact/Stress T 
~ 200 
200 300 400 too 
Bound (fmol/mg) f 
Fig. 1. Effect of Sephadex filtration of bippocampal cytosol from 0 • 
acute stressed rats on type II glucocorticoid receptor binding. Type Htpp0clmlpull Hl~0thel~us ~rtex CerebellUm Pltulteey 
II specific binding was measured with [3H]DEX (0.3-30 nM). Type 
II binding of 16 h ADX rats (open square) is compared to 
intact/stress rats. Cytosol from the intact/stress rats was divided in 
half. One fraction (open circle) was filtered through a Sephadex 
LH-20 column prior to incubation with [3H]DEX; the other fraction 
(open triangle) was placed directly into the incubation tubes. Note 
the ability of the Sephadex filtration to reduce the Kd (increase the 
slope) of the type II binding for the intact/stress rats towards that 
of the ADX rats, without altering the Bma x (X-intercept). 
Fig. 3. Brain region and pituitary comparison of type II binding of 
ADX rats and intact stressed and unstressed rats. Type II binding 
for the hypothalamus, cortex, cerebellum and pituitary was mea- 
sured with a single saturating concentration of [3H]DEX (10 nM) 
with or without the presence of RU26988 (0.5/~M), n = 4-6. The 
hippocampal binding shown is the combined Bma X values from 
Expts. 1, 2 and 4 (see Tables I, II and IV) for the 3 treatment 
groups, n = 7. *P < 0.05, **P < 0.01, significantly different from 
the ADX group for the same tissue area, Tukey test. 
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TABLE II 
Effect of low dose dexamethasone treatment (mean + S. E. M.) on hippocampal glucocorticoid receptor binding of intact and ADX rats 
Hippocampi were pooled from 3 rats for each treatment group and the mean and S.E.M. represent the results from 3 separate experiments. On 
each occasion type I binding was measured with [3H]DEX (0.3-10 nM) or [3H]aldosterone (ALDO, 0.3-6 nM) in the presence of RU26988 (0.5 
#M). Non-specific binding was determined from [3H]DEX or [3H]aidosterone binding in the presence of an excess of corticosterone (2.5/~M). 
Type If binding was measured with [3H]DEX (0.3-10 nM) with or without the presence of RU26988 (0.5/zM). n.d., not detectable. 
Treatment Type 1 ([JH]dex) Type I ([ZH]aldo) Type H 
K a B,,o~ % of ADX K a Bm~x % of ADX K a Bma~ % of ADX 
(nM) (fmol/mg) Bm~ (nM) (fmol/mg) Bm~ (nM) (fmol/mg) B,,,~ 
ADX 1.44+0.24 75.6+22.6 100 0.62+0.16 99.5+26.1 100 0.42+0.01 197.0+28.3 100 
ADX/DEX 1.89 + 0.51 87.6 + 9.2 137.8 + 40.3 0.56 + 0.09 92.9 + 15.2 102.1 + 18.7 0.40 + 0.04 122.1 + 7.8* 63.6 + 6.1 
Intact/no-stress 5.89 + 1.1"* 23.0 + 5.5* 35.6_+ 11.9 1.44 + 0.51 22.3 + 9.2* 24.6 + 9.1 0.46 + 0.07 142.9 + 9.0* 74.7 + 7.8 
Intact/DEX 1.93 + 0.26 42.1 + 3.7 67.2 + 19.2 0.65 + 0.07 47.3 + 3.3 54.9 + 14.7 0.47 + 0.08 116.2 + 1.4" 61.5 _+ 8.5 
Intact/stress n.d. n.d. 0 n.d. n.d. 0 4.16 + 0.70** 112.8 + 11.1" 58.4 + 5.0 
*P < 0.05, **P < 0.01 for significant difference from ADX group, Newman-Keuls test (n = 3). 
in b o t h  cor t ica l  and ce rebe l l a r  type  I b ind ing  for  the  
intact /s t ress  g roup  (Fig. 2). T h e r e  was a ve ry  low level  o f  
type  I b ind ing  in the  h y p o t h a l a m u s  for  all 3 t r e a t m e n t  
groups .  Type  I I  b ind ing  of  the  hypo tha l amus ,  co r t ex  and 
c e r e b e l l u m ,  in cont ras t  to the  h ippocampus ,  exh ib i t ed  a 
dec rea se  in b ind ing  on ly  for  the  intact /s tress  g roup  (Fig. 
3). T h e  p i tu i ta ry  was especia l ly  insensi t ive  to the  pres-  
ence  o f  e n d o g e n o u s  s teroid .  T h e  only  dec rease  in 
p i tu i ta ry  b ind ing  was for  type  I b inding in the  intact /s tress  
rats.  
Experiment 2. Effects o f  brief exposure to D E X  on type 
I and type H receptor binding 
D E X  is an e f fec t ive  agen t  for  suppress ing  e n d o g e n o u s  
g lucocor t ico id  and at the  s a m e  t ime  shows no  signif icant  
labe l ing  of  type  I r ecep to r s  in v ivo  29. T h e r e f o r e  we  used  
t r e a t m e n t  of  in tact  rats  wi th  D E X  in t he  dr ink ing  wa te r  
in an a t t emp t  to  revea l  m o r e  type  I r e c e p t o r  b inding  than  
is ev iden t  in the  in tac t /no-s t ress  condi t ion .  
A D X  and intact  rats  w e r e  g iven  D E X  (1 .5 /zg /ml )  in 
the  dr ink ing  wa te r  for  one  n ight  p r io r  to  sacrifice.  As  
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Fig. 4. Time and dose effect of DEX in the drinking water on hippocampal type I and type II binding. Type I binding on individual hippocampi 
was measured with [3H]aldosterone (6 nM) in the presence of RU26988 (0.5/zM); type II binding was measured with [3H]DEX (10 nM), n 
= 3-4. *P < 0.05, **P < 0.01, significantly different from the ADX group, Tukey test. 
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shown in Table II, DEX treatment had no effect on the 
Bma x of hippocampal type I receptor binding of ADX 
rats, and elevated the Bma x of intact rats to a level which 
was not significantly different from ADX rats. It should 
be noted that, in contrast to the first experiment, each 
replication of this experiment revealed a detectable type 
I signal for the intact/no-stress rats ranging from 25% to 
38% of ADX levels. Again, however, there was no 
detectable type I signal for intact/stress rats. K d values for 
type I binding were elevated in the intact/no-stress 
condition compared to intact/DEX and ADX groups. 
The type I binding levels and relative changes in K d were 
similar whether [3H]DEX or [3H]aldosterone were used 
to label type I binding, confirming the adequacy of 
[3H]DEX to measure type I binding in vitro. 
For type II receptors, overnight DEX (1.5/~g/ml) in the 
drinking water depressed the hippocampal Bma x values in 
both ADX and intact animals, without altering the K d 
values (Table II). Again, stress reduced the type II Bma x 
compared to 16 h ADX and it increased the K d value 
significantly, indicating substantial competition by unla- 
beled glucocorticoid in the cytosol. 
There was no significant difference between the serum 
CORT levels in the trunk blood of the intact/DEX rats 
(0.6 + 0.1/~g%) and the intact/no-stress rats (2.5 + 1.4 
/~g%). One hour of restraint stress prior to sacrifice 
produced a large increase in the serum CORT level (28.4 
+ 3.4/~g%). 
Experiment 3. Time course and dose response o f  D E X  
treatment on type I and type H receptor binding 
In order to investigate further the effects of DEX, 
different times and doses of exposure were utilized. 
Using single point binding assays, type I receptor binding 
was constant across the two doses and duration of DEX 
treatment, and was lower than in 16 h ADX hippocam- 
pus (Fig. 4). In contrast, there was about a 30% decrease 
in type II binding of intact rats that had DEX (1/zg/ml) 
in their drinking water for 1, 2 or 3 days (Fig. 4) and a 
significantly greater decrease (70%) with a higher dose of 
DEX (5 ~g/ml) in the drinking water for 3 days. 
Experiment 4. Estimates o f  effect o f  stress and D E X  on 
type I and type H receptor occupation and activation 
Overnight access to a dose of DEX (15 ~tg/ml) in the 
drinking water (10 times higher than the dose used in the 
second experiment) produced an almost 90% decrease in 
the Bma x for type II hippocampal binding of intact/ 
high-DEX rats or ADX/high-DEX rats, and about a 
6-fold increase in Kd, relative to ADX rats (Table III). 
Although the high dose of DEX produced a 20% 
decrease in the type I Bma x of ADX/high-DEX rats, DEX 
treatment of intact rats resulted in an elevated type I Bma ~ 
compared to the intact/no-stress rats (Table IV), as was 
also the case in the second experiment. This high dose of 
DEX, in contrast to the lower dose used in Expt. 2, 
produced a 3- to 4-fold increase in the type I Kd, 
indicating significant competitive interaction of the exo- 
genous steroid with the type I site in vitro. 
We were intrigued by the small effect of the high dose 
of in vivo DEX treatment on type I binding level in spite 
of the large shift it produced in vitro on the type I K a. 
Similarly, we noted that in vivo stress levels of CORT 
produced only a 50% decrease in type II binding 
compared to 16 h ADX, while elevating the type II K d in 
vitro by more than 10 fold. We calculated estimates of the 
concentrations of endogenous CORT remaining in the 
cytosol of intact/no-stress and intact/stress rats and of 
exogenous DEX in the cytosol of ADX/high DEX rats. 
For enzyme-substrate interactions the presence of a 
competitive inhibitor increases the measured K d by the 
factor of: 
TABLE III 
Comparison of change in hippocampal type H binding with hypothetical receptor occupancy by corticosterone or dexamethasone 
Type II binding was measured with [3H]DEX (0.3-10 nM) with or without the presence of RU26988 (0.5/~M). See Results for the equations and 
their description used to estimate the concentration of DEX or corticosterone (CORT) in the cytosol and the percent occupancy of each. The 
3 K~o m used for estimating the concentration of DEX was the K d value obtained for [ H]DEX type II binding in the cytosol from ADX rats (0.39 
nM). ~he same value was used for the Kalis. The Kdcom p used for estimating the concentration of CORT was 0.5 nM based on the type II value for 
CORT reported by others zT. 
Treatment Receptor binding values Estimated receptor occupancy 
Kdobt B,.,~ % decrease of In vivo [comp] % occupancy 
(nM) (fmol/mg) A DX B,.o~ competitor (nM) 
ADX 0.39 223.4 0 none 0 0 
ADX/high-DEX 2.31 28.7 87.2 DEX 1.9 83.1 
Intact/no-stress 0.56 150.1 32.8 CORT 1.3 30.2 
Intact/high-DEX 2.45 25.5 88.6 CORT + DEX insufficient information 
Intact/stress 4.27 112.4 49.7 CORT 29.8 90.8 
1 + ([comp]/K&:omp) 
where [comp] is the concentration of the competitor and 
gdcom p is the dissociation constant for the competitor 8. 
Applying this to ligand-receptor interactions we esti- 
mated the concentration of competing steroid present in 
the cytosol using the equation: 
Kdobt = Kdlig(1 + ([comp]/Kdcomp)) 
and solving for [comp]: 
[comp] = (Kdobt'gdcomp/Kdlig) - -  Kdcomp 
where Kdobt was the Kd obtained from the saturation 
binding assay for the treatment group of interest, Kdug 
was the K d for the radiolabeled ligand obtained from the 
saturation binding of the A D X  group (in which no 
competing ligand was assumed to be present), and Kdcom p 
was the K d of the competitor for the binding site. 
We also estimated the percent occupancy of binding 
sites by the derived steroid concentrations. The percent 
of binding sites that would be occupied (Bound/Bmax) by 
the estimated concentration of steroid was computed 
using the classic mass action law for enzyme-substrate 
interactions which has been adapted to receptor-ligand 
interactions43; the equation is: 
Bound = Bmax[Steroid]/(K d + [steroid]) 
and by rearranging, percent of total binding is: 
Bound/Bma x = [steroid]/(K d + [steroid]) 
where [steroid] was the estimated concentration of either 
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CORT or DEX and K d was the respective Kd of each 
steroid for the type I and type II  binding sites. 
Thus, we obtained an estimate of the percent of 
receptors which were occupied in vivo by CORT in the 
intact rats or by DEX in the ADX/DEX rats. This 
estimate presumes that the steroid concentration in the 
cytosol was similar to that present intraceUularly in vivo. 
The steroid concentration in the cytosol, however, is 
likely to be less than that present in vivo due to the 
dilution of tissue with buffer for homogenization. We 
compared the receptor occupancy estimates with the 
decreases in Bma x for the respective treatment groups 
relative to 16 h A D X  as measured with the binding assay. 
If all of the receptors which were occupied in vivo were 
also activated (and thus unavailable for exchange in the 
in vitro binding assay) then the estimates of percent in 
vivo occupancy by steroid should approximate the mea- 
sured percent decrease in receptor binding. We also 
assumed that the presence of molybdate in the homog- 
enization and incubation buffer prevented activation of 
receptors in vitro 1°. 
Estimates of the concentration of endogenous CORT 
in the cytosol from intact/no-stress rats, based on the shift 
in the type I and type II receptor Kds, was 1.8 nM and 
1.3 nM, respectively. These concentrations of CORT 
were calculated to produce a 70.3% occupancy of the 
type I receptor and a 30.2% occupancy of the type II 
receptor (Tables III  and IV). These estimates of receptor 
occupancy by low basal levels of CORT agree well with 
the obtained in vivo decrease in type I (74.9%) and type 
II (32.8%) binding of intact/no-stress rats. The high 
concentration of CORT found in the intact/stress rats' 
cytosol, however, was estimated to be a concentration of 
steroid (29.8 nM) sufficient to occupy 90.8% of the type 
II receptors, but this condition was associated with only 
TABLE IV 
Comparison of change in hippocampal type I binding with hypothetical receptor occupancy by corticosterone or dexamethasone 
Type I binding was measured with either [3H]DEX (0.3-10 nM) or [3H]aldosterone (0.3-6 nM) in the presence of RU26988 (0.5/~M). Binding in 
the presence of corticosterone (CORT, 2.5 ~M) was used to determine non-specific binding. Only type I binding measured with [3H]aldosterone is 
shown in this table. The concentration of DEX or cortieosterone (CORT) ([comp]) in the cytosol and the percent occupancy was estimated using 
equations described in Results. The Kdco,n p used for estimating the concentration of DEX was the K d value obtained for [3H]DEX type I binding 
in the cytosol from ADX rats (0.93 nM). The Kocom used for estimating the concentration of CORT was 3 nM based on the type I K d value for 
27 3 CORT reported by others . The Kdlig was the K d va~ue obtained for [ H]aldosterone type I binding in the cytosol from ADX rats (0.68 nM). n.d., 
not detectable. 
Treatment Receptor binding values Estimated receptor occupancy 
gdobt Bm~ % decrease of In vivo [comp] % occupancy 
(nM) (fmol/mg) ADX B,n~,  competitor (nM) 
ADX 0.68 107.3 0 none 0 0 
ADX/high-DEX 2.26 85.0 20.8 DEX 2.2 70.3 
Intact/no-stress 3.10 26.9 74.9 CORT 1.8 78.3 
Intact/high-DEX 2.83 52.2 51.4 CORT + DEX insufficient information 
Intact/stress n.d. n.d. 100 CORT insufficient information 
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TABLE V 
Uptake of [3 H]corticosterone in isolated nuclei 
[3H]Corticosterone (CORT, 150/~CI) was injected i.m. in ADX rats 
1 h before sacrifice. Nuclei were isolated from brain tissue (see 
Methods) and protein extracted from nuclei with 0.6 M KCI. After 
extraction of protein from the isolated nuclei the remaining 
[3H]CORT in the nuclear pellet was extracted with ethanol, dried 
and counted in scintillation cocktail by a scintillation counter. 
Aliquots of the protein extract were placed directly in scintillation 
cocktail and radioactivity also counted. The amount of [3H]CORT 
for the nuclear pellet reported in the table is the combined nuclear 
radioactivity content determined from the pellet ethanol extract and 
the protein extract. 
Brain tissue Nuclear pellet Protein extract 
DNA % oftotal [3H]CORT [3H]CORT 
content t i s s u e  (cpm/mg (% of pellet 
(mg) DNA DNA cpm) 
content 
Hippocampus 0.045 25.7 11643 45.2 
Amygdala 0.023 16.5 8914 45.0 
Cerebellum 0.282 16.4 816 62.8 
Cortex 0.114 20.2 2198 62.9 
Wholebrain-1 0.789 20.1 2476 55.0 
Wholebrain-2 0.740 21.6 1946 52.0 
a 49.7% decrease in binding. 
For D E X  treatment there was a good accordance 
between the percent decrease in type II binding (87.2%) 
and the estimated percent occupancy of  type II binding 
sites (83.1%) by the calculated concentration of exoge- 
nous D E X  (1.9 nM) present in the cytosol of A D X /  
high-DEX rats (Table IV). On the other hand there was 
a poor  correspondence in the two values for type I 
binding, in which there was a 20.8% decrease in binding 
while estimated levels of D E X  (2.2 nM) in the cytosol 
were sufficient to occupy 70.3% of the receptors (Table 
Ill). 
Attempt  to detect nuclear A S  receptors by an exchange 
assay 
Our data point to reduced cytosol type I and type II 
receptor availability when glucocorticoids are present in 
vivo. Because the destination of  glucocorticoid bound 
receptors is the nucleus, we attempted to exchange 
nuclear receptors labelled with [3H]CORT in vivo with 
cold C O R T  in vitro. We also attempted to label and 
exchange nuclear receptors with [3H]CORT in the 
presence or absence of an excess of cold C O R T  in vitro. 
Table V shows the nuclear uptake of [3H]CORT 
measured in different brain areas of  rats injected with 150 
btCi [3H]CORT (i.m.) 1 h before sacrifice. In agreement 
with previous results 2°, the highest concentration of 
[3H]CORT was found in the hippocampus and amygdala, 
and the lowest concentration in cerebellum, with inter- 
mediate levels in cortex or whole brain. Salt extraction 
TABLE VI 
Comparison of whole brain nuclear uptake of in vivo injection of 
[3H]corticosterone with in vitro specific nuclear binding of [3H]- 
corticosterone 
Nuclei from rat brain were isolated as described in Methods and 
nuclear protein extracted with 0.6 M KCI. Note the high amount of 
radioactivity in the protein extract from rats injected in vivo with 150 
/tCi of [3H]corticosterone (CORT, 0.5/~g) compared to the variable 
and low in vitro specific binding of [3H]CORT to protein extract from 
rats injected with vehicle, low dose or high dose of CORT 1 h before 
sacrifice (n = 3). 
Treatment Protein extract radioactivity 
(cpm/mg pellet DNA) 
[3H]CORT (150gCi) 1208 + 334 
Vehicle (sesame oil, 1 mg/kg) 103 + 103 
CORT (0.5/tg) 72 + 90 
CORT (50 mg/kg) 137 + 89 
(0.6 M KCI) of soluble proteins from the nuclear pellet 
resulted in extraction of 45-60% of the total nuclear 
radioactivity. Salt extracts from nuclei isolated from 
whole brain were used for subsequent exchange assays. 
When filtering the nuclear salt extract from rats injected 
with [3H]CORT through Sephadex LH-20 columns, 
60-100% of the total salt extract radioactivity was 
recovered, in agreement with previous work TM. Incuba- 
tion of  salt extract from rats injected with [3H]CORT 
with an excess of unlabeled C O R T  (2.5/~M) had no effect 
on the amount of radioactivity recovered from LH-20 
columns, indicating that most of  the extracted radioac- 
tivity was macromolecularly bound,  but could not be 
displaced by unlabeled CORT. There was also no 
evidence for specific binding of [3H]CORT in the 
exchange assay with salt extract of nuclei isolated from 
A D X  rats injected with either vehicle, low (0.5/~g) or 
high (50 mg/kg) dose of  unlabeled C O R T  1 h before 
sacrifice (Table VI). 
DISCUSSION 
Measurement o f  type I and type H receptors in relation to 
their activation 
These studies confirm that the presence of  endogenous 
and/or exogenous glucocorticoids in brain tissue at the 
time the animal is sacrificed results in a lower level of  AS 
receptor binding as measured in an in vitro cytosolic 
receptor binding exchange assay. The decrease in binding 
can be accounted for by the fact that AS receptors are 
unique compared to other steroid receptors. Steroid 
receptors bound to a steroid ligand become 'activated'  to 
a form which binds more tightly to D N A  enhancer 
elements 4°. Studies using cytosolic fractions have found 
that the activated form of the AS receptor, in contrast to 
other steroid receptors, is unable to exchange ligand in an 
in vitro binding assay 9. Further evidence that this is a 
general property of the activated form of the AS 
receptor, not dependent on cellular compartmentaliza- 
tion, comes from our observation that AS receptors 
extracted from isolated nuclei of rat brain also did not 
participate in an exchange assay. Our experiments have 
utilized a long incubation duration (20 h) in order to 
maximize chances for exchange by unactivated receptors 
(see below). Thus, all AS receptors which are activated 
at the time the animal is sacrificed are unavailable for 
measurement in an in vitro binding assay. Therefore, the 
lower AS binding levels of intact rats relative to ADX 
rats reflect the proportion of the steady-state level of 
receptors that are activated at the time of cytosol 
preparation. 
Taking advantage of this unique feature of AS recep- 
tors, we measured the amount of AS receptor binding in 
rats with varying levels of endogenous or exogenous 
glucocorticoids in order to make estimates of the pro- 
portion of AS receptor occupation and activation in 
various tissues during these conditions. We examined the 
degree of type I and type II AS receptor activation in the 
brains of non-ADX rats with low basal levels of circu- 
lating CORT and with high levels of CORT after acute 
stress. We found that the type I receptors in the 
hippocampus, hypothalamus and cortex were largely 
activated by low basal levels of CORT, whereas, there 
was not a significant activation of type I receptors in the 
cerebellum or pituitary. The proportion of type I recep- 
tors activated in the hippocampus ranged from 60% to 
100%. The variability may reflect small fluctuations in 
the release of CORT even during low basal conditions. 
Moderate sized pulses of ACTH release during the nadir 
period of the ACTH and CORT circadian cycle have 
recently been described 6. All of the type I receptors were 
activated in the hippocampus during acute stress, as were 
nearly all of the type I receptors in the other tissues. 
There was much less activation of type II receptors 
during both basal and stress conditions. High circulating 
CORT levels arising from acute stress produced nearly a 
50% activation of type II receptors in the various brain 
regions sampled, but interestingly, produced no activa- 
tion of type II receptors in the pituitary. On the other 
hand, the hippocampus was the only tissue examined in 
which there was a significant activation of type II 
receptors under basal conditions. The apparent height- 
ened sensitivity of the hippocampal AS receptors to 
circulating levels of CORT may partly account for the 
greater sensitivity of the hippocampus to the neurotro- 
phic and neurotoxic effects of CORT as compared to 
other brain areas 32,34. 
A differential sensitivity between the hippocampus, 
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other brain areas and the pituitary to the effect of CORT 
on AS binding levels was also observed by Brinton and 
McEwen 4. As noted in their study, the insensitivity of the 
pituitary is most likely explained by the high concentra- 
tion of CORT binding globulin (CBG) which is present 
in the pituitary 16. CBG may have buffered the pituitary 
from the fluctuating levels of endogenous CORT, such 
that the concentration of free CORT at the receptor sites 
remained quite low. There is no evidence for a similar 
mechanism, however, within different brain regions, 
where CBG levels are believed to be uniformly low, so 
the differential sensitivity of the hippocampus remains a 
mystery. 
An implication of the lack of type II receptor activation 
in the pituitary after acute stress is that in vivo the type 
II receptors of the pituitary may not participate in the 
negative feedback effect of CORT on ACTH release, 
contrary to what has been suggested based on in vitro 
studies 11. A role of type I receptors in vivo, however, 
cannot be ruled out. 
Type I and type II receptor availability in relation to 
endogenous CORT levels 
The proportion of hippocampal AS receptor activation 
during basal and acute stress conditions reported in this 
paper agree fairly well with estimates of AS receptor 
occupation under similar conditions as reported by 
others  21'27"29. The level of hippocampal type II binding 
we observed in the intact unstressed and stressed rats 
relative to that observed in 16 h ADX rats is similar to 
the relative levels of total hippocampal AS receptor 
binding of intact stressed and unstressed rats compared to 
12-14 h ADX rats as reported by Meaney et al. 21. Two 
studies by Reul and de Kloet 27 and Reul et al. 29 also 
measured both type I and type II binding of intact 
unstressed and stressed rats. In one of the studies 27 
binding levels for intact rats were compared to levels 
from 3 day ADX rats. That study reported that intact 
unstressed and intact stressed rats had low levels of type 
I binding that were 10% and 2%, respectively, of 3 day 
ADX levels. In the other study by the same group 29, 
using binding levels from 24 h ADX rats as a reference, 
the level of type I binding measured in intact unstressed 
rats was about 22% of the levels in ADX rats. 
In both studies by Reul and de Kloet 27 and by Reul et 
a129 the estimate of type II binding for intact stressed rats 
was about 25% of the binding for ADX rats, a lower 
estimate than obtained by us. The incubation duration 
used in the binding assay may be an important factor 
when there are high levels of competing steroid present 
in the tissue. In those two studies a 3 h incubation period 
was used, whereas in our studies we used a 20 h 
incubation period. Meaney et al. 21 report a substantial 
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increase in total binding levels measured for intact 
stressed rats between 4 h and 20 h of incubation. They 
suggest, as have others 13, that after only 4 h of incubation 
radiolabeled steroid has not had time to exchange with 
endogenous steroid and that the difference in binding 
obtained between 4 h and 20 h of incubation indicates 
the degree of receptor occupation, without activation, by 
endogenous steroid. 
The proportion of type I receptors occupied/activated 
during basal levels is a point of interest because it has 
been proposed by others 29 that the cell responds only to 
changes in type I receptor number, rather than to varying 
level of type I receptor occupation by steroid. This 
proposition was based on the assumption that the type I 
receptor is always at least 80% occupied by glucocorti- 
coids. Our ability to detect type I receptor levels in intact 
rats during some conditions indicating as little as 35-45% 
occupation/activation suggests that the percent of type I 
receptor activation by steroid may, at some times, be 
meaningful. 
It should be noted that our estimates of the percentage 
of receptors activated by glucocorticoids assumes that the 
difference in binding between non-ADX rats and rats 
that have been adrenalectomized for 16 h reflects only 
clearance of endogenous steroid and not any de novo 
upregulation of receptors. This is an assumption that has 
been supported by some data 19"29 but proof of a lack of 
upregulation requires other techniques which can mea- 
sure both activated and unactivated forms of the recep- 
tor. If  there is some upregulation of adrenal steroid 
receptors within 16 h after ADX then the actual percent 
occupation/activation of receptors at the diurnal nadir 
could be considerably lower than our above estimates. 
Increased type I receptor availability with DEX treatment 
Further evidence that the low level of type I binding 
that was measured in the intact unstressed rat was a result 
of receptor activation by low basal levels of endogenous 
glucocorticoids comes from the DEX treatment studies. 
Treatment of the rats with a low dose of DEX in the 
drinking water for one night resulted in a higher level of 
type I binding in the hippocampus than was measured in 
intact, unstressed rats. This increase in binding level was 
most likely a result of a lower level of endogenous steroid 
present in the tissue of the DEX treated rats as a result 
of the negative feedback effect of DEX on endogenous 
steroid levels. Scatchard analysis indicated that there was 
a considerable amount of endogenous steroid present in 
the hippocampal tissue from intact, unstressed rats which 
competed for radioligand binding in the in vitro binding 
assay, whereas there was no evidence of steroid compe- 
ting for type I binding in the hippocampal tissue of rats 
receiving low dose DEX treatment. 
Type I and type H receptor occupation and~or activation 
by CORT and DEX 
Interestingly, DEX produced very little activation of 
the type I receptor in the hippocampus, even with the 
high dose treatment which resulted in some competition 
for type I binding in vitro. Thus, DEX has a high affinity 
for type I receptors in vitro (see Methods) but does not 
interact with the receptors in vivo in such a way as to 
cause their activation. On the other hand, DEX was very 
effective at activating the type II receptor. Scatchard 
analysis, which provided information about the presence 
of competing steroid as well as level of available 
receptors, indicated that the proportion of receptor 
occupation and activation may not have been identical. 
Although activation of the AS receptor is not instanta- 
neous, the activation process is estimated to be fairly 
rapid e4, so that the difference in receptor occupation and 
activation at the time of sacrifice probably was not simply 
a result of the lag in activation time. Based on the degree 
of shift in the K d obtained for type I and type II binding 
of intact unstressed, intact stressed and ADX/high-DEX 
treated rats in our study, we estimated the concentration 
of endogenous CORT or exogenous DEX present in the 
cytosol. Then, using estimates of the type I and type II 
receptor K d for CORT and DEX we computed the 
hypothetical percent of receptors that would be occupied 
in vivo by the derived steroid concentrations. The 
percent occupancy of type I and type II receptors by 
levels of CORT in intact unstressed rats and the percent 
occupancy of type II receptors by DEX levels in 
ADX/high-DEX rats corresponded closely to the percent 
decrease in binding levels found in those cases relative to 
16 h ADX. On the other hand, two discrepancies became 
apparent: (1) stress levels of CORT were estimated to be 
of sufficient level in the cytosol to produce a 90% 
occupation of the type II receptor but produced in vivo 
only a 50% reduction in binding (i.e. 50% activation); (2) 
DEX treatment of ADX rats was estimated to produce at 
least 86% occupation of the type I receptor based on 
cytosol DEX levels, but produced in vivo only a 21% 
reduction in binding (i.e. 21% activation). 
These discrepancies suggest that there is a limited 
capacity for activation of the type II receptor by CORT 
and of the type 1 receptor by DEX. A greater efficiency 
of DEX compared to CORT in producing activation of 
AS receptors has also been noted in AtT-20 cells, which 
contain only type II receptors 37'3s. Also, in thymus cells, 
DEX was found to produce a greater proportion of 
activated to unactivated AS receptors than was produced 
by CORT 25. Munck and Holbrook propose that the 
different steady-state levels of activated to unactivated 
AS-receptor complexes is a result of a difference in the 
rate of dissociation of various hormones from the 
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activated receptor rather than an inefficiency in the 
activation process 25. 
Several behavioral deficits resulting from ADX have 
been reported which were normalized with low doses of 
CORT treatment, but not DEX treatment, leading to the 
speculation that type I receptors were responsible for the 
CORT-specific actions 15. The poor ability of DEX to 
produce or maintain activated type I receptors, in spite of 
its high affinity in vitro for type I receptors, may account 
for the ineffectiveness of DEX treatment in mediating 
effects dependent on type I receptor activity. 
Conclusion 
In summary, the hippocampus stands out as uniquely 
sensitive to the ability of low basal CORT levels to 
activate both type I and type II AS receptors. The 
proportion of type I receptors in the hippocampus which 
were unactivated or unoccupied by basal levels of CORT 
were, however, as measured in our study somewhat 
higher than has been reported by others. Furthermore, 
treatment with a low dose of DEX decreased the level of 
endogenous steroid present in the hippocampal tissue 
resulting in an increase in the number of unactivated type 
I receptors. This suggests that there may be a greater 
capacity for fluctuations in type I receptor occupation in 
vivo than had previously been suggested. AS receptors in 
the pituitary, in contrast to the hippocampus, were 
apparently largely buffered from changes in circulating 
levels of endogenous CORT. Even acute stress levels of 
glucocorticoids were unable to produce evidence for 
activation of type II receptors in the pituitary. Finally, 
the degree of AS receptor occupation and activation may 
not always be identical. CORT was less efficient at 
activating the type II receptor than the type I receptor, 
such that at higher circulating levels there was apparently 
a 90% occupation of type II receptors in the hippocam- 
pus but only 50% activation. DEX, on the other hand, 
was much more efficient at activating the type II receptor 
than the type I receptor. This may account for the 
discrepancy between the high affinity of DEX for the 
type I receptor in vitro, and its apparent low efficacy as 
a type I agonist in vivo. This may also explain why DEX 
is a much more potent glucocorticoid than CORT, even 
though the in vitro affinity of DEX for the type II 
receptor is similar to that of CORT 26. 
Although cytosolic AS receptor binding assays are 
limited by their ability to only measure the inactivated 
form of the receptor, levels of receptor binding measured 
14-24 h after ADX may closely reflect the in vivo 
steady-state level of receptors present in the animal. 
Furthermore, our results illustrated that saturation bind- 
ing studies, which provide information about the number 
of available binding sites and the potential concentration 
of steroid present at the binding sites in vivo, can assist 
in the evaluation of the state of AS receptors during 
different pharmacological treatments and physiological 
conditions. 
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